Elevance Health, Inc. $ELV Shares Purchased by TD Waterhouse Canada Inc.

TD Waterhouse Canada Inc. boosted its stake in Elevance Health, Inc. (NYSE:ELV) by 48.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,400 shares of the company’s stock after acquiring an additional 2,748 shares during the period. TD Waterhouse Canada Inc.’s holdings in Elevance Health were worth $2,796,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of ELV. PFG Investments LLC boosted its position in shares of Elevance Health by 5.2% in the 2nd quarter. PFG Investments LLC now owns 1,408 shares of the company’s stock valued at $548,000 after purchasing an additional 70 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Elevance Health by 5.7% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 40,009 shares of the company’s stock worth $15,562,000 after buying an additional 2,154 shares during the period. Ashton Thomas Securities LLC purchased a new stake in Elevance Health in the second quarter valued at approximately $418,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its holdings in shares of Elevance Health by 2.5% in the second quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 1,820 shares of the company’s stock valued at $708,000 after acquiring an additional 44 shares during the period. Finally, ZWJ Investment Counsel Inc. grew its position in shares of Elevance Health by 1.1% during the second quarter. ZWJ Investment Counsel Inc. now owns 124,131 shares of the company’s stock worth $48,282,000 after acquiring an additional 1,299 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Trending Headlines about Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Q4 earnings beat consensus (EPS beat and strong profit print), which sparked an earlier rally and helped lift investor sentiment. Elevance Health (NYSE:ELV) Stock Price Up 6.3% on Strong Earnings
• Positive Sentiment: Leerink Partners nudged its price target up to $357 and maintained a “market perform” rating, a modest vote of confidence that signals upside potential from current levels. Leerink Partners adjusts price target on Elevance Health to $357
• Positive Sentiment: Consensus broker sentiment remains constructive (average “Moderate Buy”), which provides some support for the shares as analysts digest results and guidance. Elevance Health, Inc. Given Average Recommendation of “Moderate Buy”
• Neutral Sentiment: Company Q4 call and published highlights provide detail on membership shifts, margin dynamics and the drivers behind the quarter — useful for longer-term modeling but not a clear immediate catalyst. ELV Q4 2025 Earnings Call Highlights
• Negative Sentiment: Management forecast for 2026 profit came in below some Street estimates and flagged an anticipated revenue decline, which is the principal near-term headwind pressuring the stock. Elevance forecasts 2026 profit below estimates
• Negative Sentiment: Analysts and commentary highlighted margin pressures and membership shifts shaping a weaker 2026 outlook — narratives that have driven selloffs despite the quarterly beat. ELV Q4 Deep Dive: Margin Pressures and Membership Shifts
• Negative Sentiment: Regulatory context: a CMS proposal for only a modest Medicare Advantage rate increase added to near-term investor concern, contributing to a large negative move earlier in the week. Health Insurance Stock Could Rebound Off Historically Bullish Signal
• Negative Sentiment: Coverage pieces framed the results as “in line” but stressed the deteriorating outlook and ongoing industry headwinds, which has kept selling pressure on the shares after the initial post-earnings bounce. Elevance reports Q4 in line with expectations but stock drops

Elevance Health Trading Down 0.4%

NYSE ELV opened at $345.62 on Friday. The company has a quick ratio of 1.56, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $76.81 billion, a P/E ratio of 13.76, a P/E/G ratio of 1.88 and a beta of 0.51. Elevance Health, Inc. has a 52-week low of $273.71 and a 52-week high of $458.75. The firm has a 50-day moving average price of $351.69 and a 200 day moving average price of $328.98.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.10 by $0.23. The company had revenue of $49.31 billion for the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The firm’s quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities research analysts expect that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be given a $1.72 dividend. The ex-dividend date is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 annualized dividend and a yield of 2.0%. Elevance Health’s dividend payout ratio (DPR) is currently 27.23%.

Analysts Set New Price Targets

ELV has been the subject of several research reports. Zacks Research upgraded shares of Elevance Health from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 6th. Jefferies Financial Group dropped their price objective on shares of Elevance Health from $401.00 to $395.00 and set a “buy” rating on the stock in a research note on Friday. Mizuho set a $413.00 target price on shares of Elevance Health in a report on Friday, January 9th. Wall Street Zen raised Elevance Health from a “hold” rating to a “buy” rating in a report on Saturday. Finally, UBS Group set a $400.00 price target on Elevance Health in a research report on Thursday. Thirteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Elevance Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $396.90.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.